Why the study?
β-blockers are widely used to lower heart rate during CCTA but require caution in heart failure due to potential negative inotropic effects, warranting clarification of their effects on cardiac function.
Does temporary administration of β-blockers reduce ejection fraction during CCTA in patients suspected of ischemic cardiac disease?
Does temporary administration of β-blockers reduce ejection fraction during CCTA in patients suspected of ischemic cardiac disease?
Premedication with β-blockers to lower heart rate during CCTA safely reduces heart rate without negatively impacting ejection fraction.
May support β-blocker use for heart rate control during CCTA without ejection fraction effects; leaves open need for randomized confirmation.
BACKGROUND: β-blockers are widely used for lowering heart rate (HR) during coronary computed tomography angiography (CCTA); however, they should be used with caution for patients with heart failure as they may have a negative inotropic effect. OBJECTIVE: To clarify the effects of β-blockers (oral and intravenous injection) on cardiac function using CCTA. METHODS: A total of 244 patients (men: women = 166: 78; mean age, 64.4 years old) suspected of having ischemic cardiac disease and had undergone echocardiography within 3 months before and after CCTA were included in the study. Systematic errors in ejection fraction (EF) were corrected by calculating ΔEF from the EF difference between echocardiography and CCTA in patients not using β- blockers. Univariate and multivariate analyses were performed for factors affecting ΔEF. In addition, HR between, before, and during CCTA were compared by Wilcoxon's test. RESULTS: Temporary oral or intravenous administration of β-blockers at the CCTA had no significant effects on EF (p = 0.70), whereas HR was significantly decreased (p < 0.001). However, regular administration of β-blockers increases the EF on CCTA. CONCLUSION: The administration of β-blockers immediately before CCTA affects HR but not EF. Premedication with β-blockers can be safely used for patients who undergo CCTA, and CCTA is useful for EF evaluation, independent of the use of β-blockers.
No takes yet. Share an insight, caveat, or question.
Kokubo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: